Latest Comments

Sanofi poised for explosive growth in global dermatology market

Sanofi poised for explosive growth in global dermatology market

EULAR 2017: biosimilars in rheumatology, a painful conundrum

EULAR 2017: biosimilars in rheumatology, a painful conundrum

Could a virus save your life?

Could a virus save your life?

Biosimilar drugs: US Trumped, but FDA addresses the issues

Biosimilar drugs: US Trumped, but FDA addresses the issues

Botanical healing power: does the cure for anemia really grow on trees?

Botanical healing power: does the cure for anemia really grow on trees?

Do new diabetes discoveries deliver more benefits than risks?

Do new diabetes discoveries deliver more benefits than risks?

Carefully stepping away from RCTS: clinical trial design in a new medical era

Carefully stepping away from RCTS: clinical trial design in a new medical era

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

Could Novartis’ longer-acting anti-VEGF Drug, RTH258, offset Lucentis’ loss to Eylea?

NeuPSIG 2017: sodium channel blockers highlight a new approach to neuropathic pain

NeuPSIG 2017: sodium channel blockers highlight a new approach to neuropathic pain

NeuPSIG 2017: three strategies for improving treatment options for neuropathic pain

NeuPSIG 2017: three strategies for improving treatment options for neuropathic pain

Insulin-related therapy: despite advances, unmet needs remain

Insulin-related therapy: despite advances, unmet needs remain

EULAR 2017: Lupus community remains divided on outcome measures

EULAR 2017: Lupus community remains divided on outcome measures

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

EULAR 2017: Chondroitin Sulphate surprises with good results in knee osteoarthritis

Fecal transplant-based treatment for C. difficile reaches phase III trials

Fecal transplant-based treatment for C. difficile reaches phase III trials

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Tempered optimism for early IDO + PD1 dual checkpoint blockade data in advanced urothelial carcinoma

Can survival data weaken the gold standard use of CDK4/6 inhibitors?

Can survival data weaken the gold standard use of CDK4/6 inhibitors?

Adding monoclonal antibodies to induction regimens: questions remain

Adding monoclonal antibodies to induction regimens: questions remain

Stivarga is the first FDA-approved targeted treatment for liver cancer in a decade

Stivarga is the first FDA-approved targeted treatment for liver cancer in a decade

Is tau the way forward to treat Alzheimer’s disease?

Is tau the way forward to treat Alzheimer’s disease?

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development

Unpredictable epidemiology necessitates a more empirical approach to Zika and Ebola vaccine development

Eliminating recurrent C. difficile infections: the main focus of future drug development

Eliminating recurrent C. difficile infections: the main focus of future drug development